Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Liao
W C
WC
Chang
W S
WS
Wu
F Y
FY
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology; D001932:Brain Neoplasms / Q000628:therapy; D043525:Cytosine Deaminase; D004357:Drug Synergism; D005437:Flucytosine / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D018316:Gliosarcoma / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D009700:Nucleoside Deaminases / Q000235:genetics; D011355:Prodrugs / Q000494:pharmacology; D051381:Rats; D012190:Retroviridae; D013937:Thymidine Kinase / Q000235:genetics
D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D011355:Prodrugs; D005437:Flucytosine; D013937:Thymidine Kinase; D009700:Nucleoside Deaminases; D043525:Cytosine Deaminase; D015774:Ganciclovir